Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of erucic acid in preparing medicine for preventing or treating vaccinum influenzae vivum

A technology of influenza A and influenza A virus, which is applied in the field of medicine, can solve the problems that the effect of erucic acid has not been reported, and achieve the effect of meeting the needs of large-scale production, not easy to drug resistance, and clear structure

Active Publication Date: 2018-05-11
GUANGZHOU INST OF RESPIRATORY DISEASE +2
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there has been no report on the effect of erucic acid on inhibiting virus replication and inhibiting the inflammatory response mediated by influenza A virus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of erucic acid in preparing medicine for preventing or treating vaccinum influenzae vivum
  • Application of erucic acid in preparing medicine for preventing or treating vaccinum influenzae vivum
  • Application of erucic acid in preparing medicine for preventing or treating vaccinum influenzae vivum

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] The inhibitory effect of embodiment one erucic acid on common influenza virus causing cytopathic

[0021] 1. Materials: cells and viruses

[0022] Low-generation MDCK cells (less than 25 generations) were purchased from ATCC and kept in our laboratory; A / PR / 8 / 34(H1N1), A / GZ / GIRD07 / 09(H1N1), A / HK / 8 / 68( H3N2), A / HK / Y280 / 97 (H9N2), B / Lee / 1940 (FluB) are preserved in our laboratory.

[0023] 2. Reagents:

[0024] DMEM / DF12 (1:1) medium was purchased from Gibco Company; MTT was purchased from Sigma Company, 5mg / mL MTT solution=50mg of MTT+100mL DMEM / DF12 (1:1) medium; virus culture solution (containing final concentration 1.5ug / mL TPCK trypsin): 100mL DMEM / DF12 (1:1) culture solution + 150uL 1mg / mL TPCK trypsin, ready to use; erucic acid is isolated from the traditional Chinese medicine Radix Isatidis as white powder, prepared The method is carried out with reference to the literature [Modern Medicine and Clinic, 2011, 26(5): 381-383], and can also be obtained through mar...

Embodiment 2

[0039] Embodiment dierucic acid is to the inhibitory action of influenza A / PR8 / 3 / 4 (H1N1) cell culture supernatant progeny virus

[0040] 1. Materials: cells and viruses

[0041] A549 cells were purchased from ATCC and kept in our laboratory

[0042] 2. Inhibitory effect of erucic acid on influenza A / PR8 / 3 / 4 (H1N1) progeny virus

[0043] 1) Discard the original medium of A549 cells in a single layer of 6-well plate, add PBS and wash twice;

[0044] 2) Add serum-free DMEM / DF12 (1:1) medium containing influenza virus A / PR8 / 3 / 4 (H1N1), and adsorb cells at 37°C for 2 hours;

[0045] 3) wash the cells with PBS to remove unadsorbed virus;

[0046] 4) The drug treatment mode was adopted. Different concentrations of erucic acid (100 μg / ml, 200 μg / ml, 300 μg / ml) were added to the drug intervention group, and 200 μg / ml erucic acid was added to the drug-only group. The A549 cells in the drug-only group were free from influenza. Virus adsorption, culture at 37°C for 24 hours;

[0047...

Embodiment 3

[0053] The effect of embodiment trierucic acid on influenza virus A / PR8 / 3 / 4 (H1N1) inducing host signaling pathway

[0054] 1. Chemical reagents and antibodies

[0055] Sodium chloride (NaCl), potassium chloride (KCl), potassium dihydrogen phosphate (KH2PO4), disodium hydrogen phosphate (Na2HPO4·12H2O), glycine Glycine, and Tween Tween-20 were all purchased from Guangzhou Chemical Reagent Factory; Tris base purchased from Ameresco; sodium dodecylsulfonate (SDS) was purchased from Sigma, USA; ammonium persulfate (APS) was purchased from Ameresco, USA; TEMED (N,N-methylenebisacrylamide) was purchased from Bio -rad company; RIPA lysate was purchased from American Thermo Company; PMSF was purchased from American Sigma Company; Cocktail (protease inhibitor) was purchased from American Sigma Company; BCA protein concentration assay kit was purchased from American Thermo Company; Easysee Western marker (20- 90kDa) was purchased from China TransgenBiotech Company; Blue plus II protei...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides new application of erucic acid in preparing a medicine for preventing or treating vaccinum influenzae vivum. The invention also provides the medicine for preventing or treatingvaccinum influenzae vivum. The medicine is prepared from the active ingredient erucic acid. The inventor finds that the erucic acid has remarkable inhibitory activity on vaccinum influenzae vivum replicated and mediated inflammatory reaction. A liquid chip technology is adopted to prove that the erucic acid can remarkably inhibit the abnormal expression of an H1N1 virus infected A549 cell inflammatory factor and is in a dose-dependent relationship; an immunoblotting method is adopted to prove that the erucic acid can inhibit activation of a host inflammation-associated signal path and is in adose-dependent relationship; Annexin V-FITC / PI double-tagging flow cytometry is adopted to prove that the erucic acid can remarkably inhibit apoptotic lesion of a flue H1N1 induced host cell and is ina dose-dependent relationship. Animal experiments prove that the erucic acid can remarkably inhibit lung inflammation and apoptotic lesion induced by vaccinum influenzae vivum H1N1, and the survivaltime of rats is effectively prolonged.

Description

technical field [0001] The invention belongs to the field of medicine and relates to the application of a natural product in the preparation of anti-influenza drugs, in particular to the new application of erucic acid in the preparation of drugs for preventing or treating influenza A. Background technique [0002] Influenza (abbreviated as flu) is an acute respiratory disease caused by influenza virus, which is highly contagious. The global annual incidence of influenza is about 5%-10% in adults and 20%-30% in children, and it is easy to cause hospitalization and death in high-risk groups such as infants, the elderly or patients with chronic diseases. Influenza causes about 3 million to 5 million cases of severe disease and about 250,000 to 500,000 deaths every year in the world, seriously threatening human life and health and causing huge economic losses. Human influenza viruses are divided into three types: A, B, and C. Among them, influenza A is the most threatening to h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/201A61P31/16
CPCA61K31/201
Inventor 杨子峰李菁梁晓丽周倍贤潘锡平钟南山
Owner GUANGZHOU INST OF RESPIRATORY DISEASE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com